Collagenases are naturally occurring enzymes responsible for the breakdown of collagen. BioSpecifics has developed a specific collagenase formulation, Collagenase Clostridium Histolyticum (CCH), for the treatment of conditions associated with excess collagen formation. These vary from topical indications such as wound debridement (sold to Smith and Nephew and marketed as Santyl) to indications such as Peyronie’s disease and Dupuytren’s contracture, which are treated by injection. The latter are sold and marketed by Endo under the name XIAFLEX®, with BioSpecifics retaining a royalty interest.